In Brief: Pfizer earnings, NAD decision, DXM bill, FDA warning, regulatory agenda
This article was originally published in The Tan Sheet
Executive Summary
Pfizer’s OTC pain sales drop; NAD Procera AVH claims to FTC; House introduces DXM bill; FDA warns medical food firm; Regulatory Agenda pushes back OTC actions; meetings address terrorism-related food adulteration; and more news In Brief.
You may also be interested in...
FSA/HSA Coverage Tops CHPA 2014 Legislative Goals
The Consumer Healthcare Products Association’s No. 1 legislative priority in 2014 is restoring OTC coverage by flexible spending and health savings accounts, followed by a “close No. 2” goal of establishing an age requirement to buy DXM products. Other goals include protecting access to PSE products and blocking take-back programs.
FDA Says Antiseptics Need Testing Or Face Reformulation, Relabeling
FDA proposes to amend the OTC antiseptic drug product monograph to require more detailed safety and efficacy tests, pointing to mounting data that shows antibacterial wash products could pose health risks and contribute to increase antibacterial resistance.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”